Broken up by sectors, Pfizer earned $10.5 billion with vaccines, $9.7 billion with hospital, $3.1 billion with oncology and $2.4 billion with internal medicine. Its manufacturing side, Pfizer CentreOne, brought in $317 million.
Three more things to know, according to the report:
1. So far this year, the pharmaceutical company earned $53.4 billion in revenue, and half of that number is because of its vaccine research, development and manufacturing side. The report shows a 47 percent increase in second-quarter revenue compared to 2021’s second quarter.
2. Pfizer anticipates its COVID-19 vaccine will bring in $32 billion in revenue in fiscal year 2022 and that its antiviral, at-home treatment Paxlovid will bring in $22 billion.
3. Recent developments during the second quarter include the FDA and CDC’s authorization of Pfizer’s COVID-19 vaccine for children between 6 months and 5 years old and its work to test an updated vaccine against omicron’s dominating subvariants.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
